Acquired amegakaryocytic thrombocytopaenic purpura (AATP) is a rare haematological condition characterised by isolated thrombocytopaenia with normal other cell lines. It is often initially misdiagnosed as immune thrombocytopaenic purpura but has characteristic bone marrow findings of reduced megakaryocyte numbers. The optimal treatment of AATP is not clearly defined but revolves around immunosuppressive therapies. We report a case of successful treatment of AATP with danazol, an antioestrogenic medication. We also review the aetiologies and pathogenesis of the disorder and suggest that danazol should be considered as an effective alternative to potent immunosuppression in AATP.
CITATION STYLE
Mulroy, E., Gleeson, S., & Chiruka, S. (2015). Danazol: An Effective Option in Acquired Amegakaryocytic Thrombocytopaenic Purpura. Case Reports in Hematology, 2015, 1–4. https://doi.org/10.1155/2015/171253
Mendeley helps you to discover research relevant for your work.